BEIGENE, LTD. : Stock Market News and Information | BGNE| US07725L1026
BEIGENE, LTD. : News, information and stories for BEIGENE, LTD. | Nasdaq: BGNE | Nasdaq
Stay updated with breaking news from Lai Wang. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
BEIGENE, LTD. : News, information and stories for BEIGENE, LTD. | Nasdaq: BGNE | Nasdaq
NMPA grants approval for first-line use in combination with chemotherapy in advanced gastric or gastroesophageal junction adenocarcinoma with high PD-L1 expression BeiGene (NASDAQ: BGNE; HKEX:
The China NMPA has accepted BeiGene’s supplemental biologics license application (sBLA) for tislelizumab to treat hepatocellular carcinoma (HCC).
Submission seeks marketing authorization for first-line treatment of unresectable or metastatic hepatocellular carcinoma BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company
Submission seeks marketing authorization for first-line use in combination with chemotherapy in advanced esophageal squamous cell carcinoma BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global